Unlocking the therapeutic potential of secreted proteins

Restoring tissue health and rejuvenating lives

Protein signaling dysregulation leads to degenerative diseases

Juvena maps the therapeutic potential of natural secreted proteins and engineers them into biologics that restore tissue homeostasis

Restoring tissue health by repairing protein signaling and intercellular communication

Secreted proteins are released by cells to direct cellular repair, promote tissue regeneration, and drive healthy communication between different body systems. As our bodies age or as a result of genetic mutations, protein signaling can become dysregulated leading to a loss of tissue homeostasis. The resulting tissue degeneration manifests as a loss of healthy bodily functions and onset of chronic diseases.

 

Juvena’s platform mines thousands of proteins secreted by human stem cells, screens their potential to restore tissue homeostasis, and engineers novel biologic medicines into life-saving treatments.

Our mission

Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize disease-modifying biologics to treat chronic and metabolic diseases.

Our mission

Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize disease-modifying biologics to treat chronic and metabolic diseases.

Our approach

We are achieving this through a fully integrated, end-to-end artificial intelligence-enabled platform that combines a diverse protein library, in silico mapping of secreted proteins to specific disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering capabilities.

AI-powered analysis drives rapid expansion of our protein candidate library, hit generation and target validation

In vivo validation of protein bioactivity enables optimization of clinical impact and safety

Advanced protein engineering synthesizes novel biologics

Translating powerful proteins into transformative therapeutics

Juvena has developed new tools to overcome translational barriers and pioneer treatments like our first-in-class myotonic dystrophy program. We partnered with the Myotonic Dystrophy Foundation to deliver transformative outcomes for patients.

Myotonic Dystrophy Type 1 is a genetic disorder causing progressive muscle degeneration and metabolic impairments. It impacts skeletal muscle and frequently disrupts cardiac conduction, respiration, swallowing, and cognitive function.

Additional metabolic diseases Juvena focuses on include obesity, sarcopenia, lung and liver diseases.

Learn about our flagship lead biologic asset and our other programs utilizing the power of secreted proteins to make an unprecedented impact against unhealthy aging and diseases.

Translating powerful proteins into transformative therapeutics

Juvena has developed new tools to overcome translational barriers and pioneer treatments like our first-in-class myotonic dystrophy program. We partnered with the Myotonic Dystrophy Foundation to deliver transformative outcomes for patients.

Myotonic Dystrophy Type 1 is a genetic disorder causing progressive muscle degeneration and metabolic impairments. It impacts skeletal muscle and frequently disrupts cardiac conduction, respiration, swallowing, and cognitive function.

Additional metabolic diseases Juvena focuses on include obesity, sarcopenia, lung and liver diseases. 

Learn about our flagship lead biologic asset and our other programs utilizing the power of secreted proteins to make an unprecedented impact against unhealthy aging and diseases.

Accelerating disease-modifying biologics through innovation and collaboration

We are leveraging an AI-enabled platform to systematically map the therapeutic potential of secreted proteins and engineer them into novel therapeutics. Learn more about our growing pipeline.

We are always looking to advance research with synergistic partnerships. Contact us today to learn more about partnering or investing with us.

Read what top news outlets are saying about Juvena

January 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

January 2024

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”

November 2023

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.

September 2023

National Institute on Aging Spotlights our CEO’s scientific journey and Juvena Therapeutics mission to unlock the secrets of tissue regeneration

August 2023

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare

May 2023

Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive

November 2022

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging.

We’ve brought together a team of brilliant minds to unlock the potential of the human body

Be part of the team that’s decoding secreted proteins to improve human health